Description: Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.
Home Page: www.glpg.com
GLPG Technical Analysis
Generaal De Wittelaan L11 A3
Mechelen,
2800
Belgium
Phone:
32 1 534 29 00
Officers
| Name | Title |
|---|---|
| Mr. Bart Filius M.B.A., MBA | Pres, COO & Member of Management Board |
| Dr. Andre Hoekema Ph.D. | Chief Bus. Officer & Member of Management Board |
| Dr. Walid Abi-Saab | Chief Medical Officer & Member of Management Board |
| Mr. Michele Manto M.B.A. | Chief Commercial Officer & Member of Management Board |
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman & Member of Management Board |
| Ms. Elizabeth Goodwin | VP of Investor Relations |
| Ms. Sofie Van Gijsel | Head of Investor Relations |
| Marieke Vermeersch | Head of Corp. Communication |
| John Montana | Managing Director of Argenta |
| Ms. Chantal Tasset | Head of Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 81.3008 |
|---|---|
| Trailing PE: | 465.3 |
| Price-to-Book MRQ: | 0.9452 |
| Price-to-Sales TTM: | 4.5411 |
| IPO Date: | 2005-05-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 1357 |